ROCK HILL, S.C. - 3D Systems (NYSE:DDD) has obtained FDA clearance for a novel dental product, marking a significant advancement in the field of digital dentistry. The company's latest innovation, a multi-material, monolithic jetted denture solution, is designed to enhance the efficiency of dental laboratories and improve the patient experience with more durable and aesthetically pleasing dentures.
The FDA's 510(k) clearance endorses the use of two proprietary materials by 3D Systems: NextDent® Jet Denture Teeth and NextDent® Jet Denture Base. These materials, combined with the company's jetting technology, software, and services, allow the production of one-piece dentures that boast superior break resistance and visual appeal.
Glidewell, a leading dental laboratory, has been an early adopter of this technology through its partnership with 3D Systems. The lab is integrating the jetted denture solution into its workflow, aiming to offer a superior denture product to its customers. "We've worked with 3D Systems for many years, and using their digital dentistry solutions has helped us achieve tremendous success for our patients," said Stephenie Goddard, CEO of Glidewell.
The introduction of this technology is expected to significantly expand 3D Systems' footprint in the dental market. With the global market for 3D printed dentures projected to surpass $2 billion by 2028, the company's digital dentistry solutions are well-positioned to meet the increasing demand for personalized and high-quality dental prosthetics.
The jetted denture solution is part of 3D Systems' strategic initiative to broaden its portfolio in the dental sector, focusing on alignment, protection, repair, and replacement of teeth. "Our jetted denture solution reflects our commitment to the dental laboratory by offering a complete system that enhances automation and profitability within a traditionally labor-intensive workflow," said Neil McCaffrey, vice president & general manager, dental, 3D Systems.
This development is in line with the growing trend of digitalization in dental clinics worldwide. The benefits of 3D printing in prosthodontics include reduced material waste, lower capital investment, quicker turnaround times, and improved comfort and fit for patients.
For further information on 3D Systems' jetted denture solution, the company directs interested parties to its website. This announcement is based on a press release statement.
In other recent news, 3D Systems has been making significant advances. The company received FDA clearance for their TOTAL ANKLE Patient-Matched Guides, a product developed in collaboration with Smith+Nephew to enhance the precision of ankle replacement surgeries. On the financial front, despite a decline in consolidated revenue for the first half of 2024 due to weaker hardware sales, the company secured a nearly $250 million contract in the dental sector and projected full-year revenues between $450 million and $460 million.
Analysts at Lake Street Capital Markets, Loop Capital, and Cantor Fitzgerald have adjusted their price targets for 3D Systems, while maintaining their respective Buy, Hold, and Overweight ratings. This comes after the company amended its 2015 Incentive Plan, introducing 4 million new shares available for awards and extending the plan to 2034, and regained compliance with New York Stock Exchange listing standards.
In terms of partnerships, Baker Hughes, a global energy technology company, has successfully implemented Oqton Manufacturing OS, a software solution for additive manufacturing, which is a product of Oqton, a subsidiary of 3D Systems. This implementation has led to significant advancements in efficiency and cost reduction. These recent developments highlight 3D Systems' ongoing efforts to expand and innovate in their operations.
InvestingPro Insights
As 3D Systems (NYSE:DDD) garners FDA clearance for its innovative dental product, the financial metrics and market sentiment surrounding the company provide a broader context for evaluating its potential growth trajectory. According to recent data, 3D Systems has a market capitalization of $320.58 million, indicating its size within the industry. Despite the company's technological advancements, InvestingPro Tips suggest caution due to a significant cash burn rate and downward earnings revisions by analysts for the upcoming period. Moreover, the company's valuation implies a poor free cash flow yield, which could be a concern for investors looking for strong cash generation capabilities.
While the company has seen a significant return over the last week, with a 26.02% price total return, the stock price movements have been quite volatile, which could suggest higher risk for investors. Additionally, the stock price has experienced a notable decline over the past year, with a 51.19% drop in total return. This performance aligns with the broader trend of price declines over the last decade, as highlighted by an InvestingPro Tip. The current price of 3D Systems' shares stands at $2.4, which is 35.04% of its 52-week high, reflecting the recent downturn in its stock value.
Investors interested in 3D Systems' financial health may note that the company operates with a moderate level of debt and its liquid assets exceed short-term obligations, which could provide some financial flexibility in the near term. However, analysts do not anticipate the company will be profitable this year, and it has not been profitable over the last twelve months, emphasizing the importance of strategic growth initiatives like the FDA-approved dental product to potentially reverse this trend.
For those seeking a deeper dive into 3D Systems' financial outlook and strategic positioning, InvestingPro offers a comprehensive range of additional tips. There are currently 14 additional InvestingPro Tips available, providing a more nuanced understanding of the company's performance and future prospects, which can be accessed at Investing.com/pro/DDD.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.